Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.040
-0.020 (-0.49%)
Mar 20, 2026, 10:00 AM EDT - Market open
Aquestive Therapeutics Revenue
In the year 2025, Aquestive Therapeutics had annual revenue of $44.55M, down -22.61%. Aquestive Therapeutics had revenue of $13.02M in the quarter ending December 31, 2025, with 9.67% growth.
Revenue (ttm)
$44.55M
Revenue Growth
-22.61%
P/S Ratio
11.12
Revenue / Employee
$303,027
Employees
147
Market Cap
493.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.55M | -13.02M | -22.61% |
| Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
| Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
| Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
| Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
| Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
| Dec 31, 2019 | 52.61M | -14.82M | -21.98% |
| Dec 31, 2018 | 67.43M | 512.00K | 0.77% |
| Dec 31, 2017 | 66.92M | 15.13M | 29.22% |
| Dec 31, 2016 | 51.79M | 49.07M | 1,807.37% |
| Dec 31, 2006 | 2.72M | 592.00K | 27.89% |
| Dec 31, 2005 | 2.12M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 837.32M |
| Emergent BioSolutions | 742.90M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
AQST News
- 3 hours ago - Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. - GlobeNewsWire
- 7 days ago - Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation - Seeking Alpha
- 8 days ago - AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt - PRNewsWire
- 9 days ago - Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval - Seeking Alpha
- 10 days ago - Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewsWire
- 13 days ago - AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics - Business Wire
- 14 days ago - Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript - Seeking Alpha